JPH07206676A - 糖尿病の治療用薬剤 - Google Patents

糖尿病の治療用薬剤

Info

Publication number: JPH07206676A
Authority: JP; Japan
Prior art keywords: acid; lipoic acid; drug; insulin; diabetes mellitus
Prior art date: 1993-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6318836A

Other languages

English (en)

Japanese (ja)

Inventor

Klaus Wessel

ヴェッセルクラウス

Harald Dr Borbe

ボルベハラルト

Heinz Ulrich

ウルリッヒハインツ

Helmut Hettche

ヘッチェヘルムート

Hans Bisswanger

ビスヴァンガーハンス

Lester Packer

パッカーレスター

Amira Klip

クリップアミラ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Asta Medica GmbH

Original Assignee

Asta Medica GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-21

Filing date

1994-12-21

Publication date

1995-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6505606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH07206676(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-21 Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH

1995-08-08 Publication of JPH07206676A publication Critical patent/JPH07206676A/ja

Status Pending legal-status Critical Current

Links

206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 28
239000003814 drug Substances 0.000 title claims abstract description 16
229940079593 drug Drugs 0.000 title claims abstract description 12
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 37
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract description 35
150000003839 salts Chemical class 0.000 claims abstract description 14
238000011282 treatment Methods 0.000 claims abstract description 14
150000001408 amides Chemical class 0.000 claims abstract description 11
150000002148 esters Chemical class 0.000 claims abstract description 11
239000002207 metabolite Substances 0.000 claims abstract description 11
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 36
206010022489 Insulin Resistance Diseases 0.000 claims description 21
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 19
102000004877 Insulin Human genes 0.000 claims description 18
108090001061 Insulin Proteins 0.000 claims description 18
229940125396 insulin Drugs 0.000 claims description 18
108091052347 Glucose transporter family Proteins 0.000 claims description 15
102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 6
230000002829 reductive effect Effects 0.000 claims description 4
208000002177 Cataract Diseases 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 3
208000017169 kidney disease Diseases 0.000 claims description 3
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
108010078791 Carrier Proteins Proteins 0.000 claims description 2
239000003472 antidiabetic agent Substances 0.000 claims description 2
229940125708 antidiabetic agent Drugs 0.000 claims description 2
201000001119 neuropathy Diseases 0.000 claims description 2
230000007823 neuropathy Effects 0.000 claims description 2
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 2
208000033808 peripheral neuropathy Diseases 0.000 claims description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
229940126585 therapeutic drug Drugs 0.000 claims 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
229930003268 Vitamin C Natural products 0.000 claims 1
229930003427 Vitamin E Natural products 0.000 claims 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims 1
239000012752 auxiliary agent Substances 0.000 claims 1
235000017471 coenzyme Q10 Nutrition 0.000 claims 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims 1
239000003381 stabilizer Substances 0.000 claims 1
229940035936 ubiquinone Drugs 0.000 claims 1
235000019154 vitamin C Nutrition 0.000 claims 1
239000011718 vitamin C Substances 0.000 claims 1
229940046009 vitamin E Drugs 0.000 claims 1
235000019165 vitamin E Nutrition 0.000 claims 1
239000011709 vitamin E Substances 0.000 claims 1
239000008103 glucose Substances 0.000 abstract description 18
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
230000000694 effects Effects 0.000 abstract description 17
229960002663 thioctic acid Drugs 0.000 abstract description 14
235000019136 lipoic acid Nutrition 0.000 abstract description 11
101710088194 Dehydrogenase Proteins 0.000 abstract description 9
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract description 9
IZFHEQBZOYJLPK-ZETCQYMHSA-N (S)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@H](S)CCS IZFHEQBZOYJLPK-ZETCQYMHSA-N 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000000243 solution Substances 0.000 description 10
210000001519 tissue Anatomy 0.000 description 8
AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
239000003826 tablet Substances 0.000 description 6
230000005945 translocation Effects 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
239000000203 mixture Substances 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000003708 ampul Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
210000000663 muscle cell Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
102000042092 Glucose transporter family Human genes 0.000 description 2
208000007976 Ketosis Diseases 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000037149 energy metabolism Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000003538 oral antidiabetic agent Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
RGQLDLUVIDCIBI-UHFFFAOYSA-N 3-(dithiolan-3-yl)propanoic acid Chemical compound OC(=O)CCC1CCSS1 RGQLDLUVIDCIBI-UHFFFAOYSA-N 0.000 description 1
108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010000410 Acetonaemia Diseases 0.000 description 1
208000022309 Alcoholic Liver disease Diseases 0.000 description 1
208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
241000134914 Amanita muscaria Species 0.000 description 1
241000112623 Bolbe Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010023388 Ketonuria Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000017795 Perilipin-1 Human genes 0.000 description 1
108010067162 Perilipin-1 Proteins 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
206010036106 Polyneuropathy alcoholic Diseases 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108091006296 SLC2A1 Proteins 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
230000001760 anti-analgesic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
XISKMNBBUQQBBE-ANUZYNSFSA-N bisnordihydrotoxiferine Chemical compound C12C/3=C\N(C4\5)C6=CC=CC=C6C44CCN(C\C6=C\C)C4CC6C/5=C/N1C1=CC=CC=C1C21CCN2C/C(=C/C)C\3CC21 XISKMNBBUQQBBE-ANUZYNSFSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
239000000571 coke Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000002342 diabetic polyneuropathy Diseases 0.000 description 1
SHMXLCRUTGTGGS-UHFFFAOYSA-N dithiolane-3-carboxylic acid Chemical compound OC(=O)C1CCSS1 SHMXLCRUTGTGGS-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000000081 effect on glucose Effects 0.000 description 1
239000007911 effervescent powder Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
230000004136 fatty acid synthesis Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000598 lipoate effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000011045 prefiltration Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000006318 protein oxidation Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
229940005605 valeric acid Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP6318836A 1993-12-21 1994-12-21 糖尿病の治療用薬剤 Pending JPH07206676A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4343593A DE4343593C2 (de)	1993-12-21	1993-12-21	Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4343593.9		1993-12-21

Publications (1)

Publication Number	Publication Date
JPH07206676A true JPH07206676A (ja)	1995-08-08

Family

ID=6505606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6318836A Pending JPH07206676A (ja)	1993-12-21	1994-12-21	糖尿病の治療用薬剤

Country Status (10)

Country	Link
US (4)	US5693664A (de)
EP (2)	EP0958816B1 (de)
JP (1)	JPH07206676A (de)
AT (2)	ATE319444T1 (de)
CA (1)	CA2138558C (de)
DE (3)	DE4343593C2 (de)
DK (2)	DK0659408T3 (de)
ES (2)	ES2258302T3 (de)
GR (1)	GR3036943T3 (de)
PT (2)	PT659408E (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998023606A1 (en) *	1996-11-27	1998-06-04	Fuji Kagaku Kogyo Kabushiki Kaisha	Cyclic dithio derivatives, remedies for diabetic kidney diseases, hypoglycemic agents, hypolipidemic agents, and lenitives for digestive disorders
JP2000169371A (ja) *	1998-10-02	2000-06-20	Sankyo Co Ltd	ジチオラン誘導体を含有する医薬
JP2002516270A (ja) *	1998-05-28	2002-06-04	メディカルリサーチインスティチュート	リポ酸の制御放出
JP2004508399A (ja) *	2000-09-12	2004-03-18	ビーエーエスエフ　アクチェンゲゼルシャフト	糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ
JP2004531567A (ja) *	2001-05-28	2004-10-14	エスパルマゲーエムベーハー	薬剤
JP2005002096A (ja) *	2003-05-21	2005-01-06	Oga Research:Kk	α−リポ酸含有水性製剤
JP2006321732A (ja) *	2005-05-18	2006-11-30	Fancl Corp	異常蛋白質除去及び８−ヒドロキシ２’−デオキシグアノシン増加抑制用組成物
WO2011152658A3 (en) *	2010-06-01	2012-04-26	Celltrion Chemical Research Institute	Pharmaceutical composition comprising piperazine dithioctate and glimepiride
JP2021059552A (ja) *	2014-10-20	2021-04-15	ヴァルビオティス	植物抽出物の混合物、またはこの植物中に含まれる分子の混合物を含有する組成物、ならびに糖質代謝及び／または脂質代謝を制御するための使用

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4343593C2 (de) *	1993-12-21	1998-05-20	Asta Medica Ag	Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4433764A1 (de) *	1994-09-22	1996-03-28	Asta Medica Ag	Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
US6752999B2 (en)	1995-09-20	2004-06-22	Nicholas V. Perricone	Method of skin care and/or treatment using lipoic acid
US7438896B2 (en) *	1995-09-20	2008-10-21	N.V. Perricone Llc	Method of skin care using lipoic and ascorbic acids
EP0855396A1 (de) *	1997-01-22	1998-07-29	ASTA Medica Aktiengesellschaft	Metabolite von Thioctsäure und deren Verwendung
DE19705555A1 (de) *	1997-02-13	1998-08-20	Ulrich Dr Posanski	Pharmazeutische Präparate der Thioctsäure zur oralen Anwendung
IL123887A0 (en)	1997-04-02	1998-10-30	Sankyo Co	Dithiolan derivatives their use and pharmaceutical compositions containing the same
US6472432B1 (en)	1997-11-17	2002-10-29	Nicholas V. Perricone	Treatment of rosacea using lipoic acid
US5965618A (en) *	1997-11-17	1999-10-12	Perricone; Nicholas V.	Treatment of scar tissue using lipoic acid
US6365623B1 (en)	1997-11-17	2002-04-02	Nicholas V. Perricone	Treatment of acne using lipoic acid
DE19806354B4 (de) *	1998-02-10	2004-09-16	Bdd Group Holding Ag	Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
US6090842A (en) *	1998-03-10	2000-07-18	The Regents Of The University Of California	Lipoic acid analogs
US6905707B2 (en) *	1998-05-28	2005-06-14	Medical Research Institute	Controlled release arginine alpha ketoglutarate
US20040259895A1 (en) *	1998-05-28	2004-12-23	Medical Research Institute	Oral formulation of lipid soluble thiamine and lipoic acid
US20060024367A1 (en) *	1998-05-28	2006-02-02	Byrd Edward A	Controlled release alpha lipoic acid formulation with an inositol compound
US20050085498A1 (en) *	1998-05-28	2005-04-21	Byrd Edward A.	Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6191162B1 (en)	1998-05-28	2001-02-20	Medical Research Institute	Method of reducing serum glucose levels
US20010041187A1 (en) *	1998-10-20	2001-11-15	Carl W Hastings	Performance-enhancing dietary supplement
US6288106B1 (en) *	1999-05-25	2001-09-11	Chronorx, Llc	Processes for the synthesis and use of various α-lipoic acid complexes
WO2000072854A1 (en) *	1999-06-02	2000-12-07	Ashni Naturaceuticals, Inc.	A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine
DE19954321A1 (de)	1999-11-11	2001-07-26	Asta Medica Ag	Erleichterte Verabreichung von alpha-Liponsäure oder Derivaten derselben
US6387945B2 (en) *	2000-04-11	2002-05-14	The Regents Of The University Of California	Lipoic acid analogs
DK1294353T3 (da) *	2000-06-06	2006-07-10	Basf Ag	Anvendelse af en (R) -enantiomer af liponsyre i kosmetiske og dermatologiske sammensætninger
EP1172110A3 (de) *	2000-07-07	2003-09-17	Basf Aktiengesellschaft	Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
DE10048531C1 (de) *	2000-09-30	2002-04-25	Porsche Ag	Kühlluftführung für Kraftfahrzeuge
JP2004514716A (ja)	2000-11-30	2004-05-20	ビーエーエスエフ　アクチェンゲゼルシャフト	リポ酸およびジヒドロリポ酸の調製方法
US6359075B1 (en)	2001-01-09	2002-03-19	Bridgestone/Firestone, Inc.	Means of producing high diblock content thermoplastic elastomers via chain transfer
DE10113974B4 (de) *	2001-03-22	2008-05-29	Alzchem Trostberg Gmbh	Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits
IL158006A0 (en) *	2001-04-30	2004-03-28	Trommsdorff Arzneimittel	Pharmaceutically active uridine esters
DE10137381A1 (de)	2001-07-31	2003-02-13	Viatris Gmbh	Neue Modifikationen des Trometamolsalzes der R-Thioctsäure sowie Verfahren zu ihrer Herstellung
AU2002352726A1 (en)	2001-11-15	2003-06-10	Galileo Laboratories, Inc.	Formulations and methods for treatment or amelioration of inflammatory conditions
AU2002254546A1 (en) *	2002-04-03	2003-10-20	Mitchell A. Avery	Lipoic acid analogs useful as provitamins and antioxidants
US6733793B2 (en)	2002-06-04	2004-05-11	Metaproteomics, Llc	Oral composition with insulin-like activities and methods of use
US20050256178A1 (en) *	2002-08-23	2005-11-17	Eggersdorfer Manfred L	Novel nutraceutical compositions comprising boitin
ITMI20032528A1 (it) *	2003-12-19	2005-06-20	Francesco Santangelo	Uso di cistina o di cisteina per la prevenzione e il
US20070292888A1 (en) *	2004-03-24	2007-12-20	Gen-Path Pharmaceuticals, Inc.	Methods for Measuring Enzyme Activities in Cells, Blood, Tumors and Tissues
DE102004050353A1 (de) *	2004-10-15	2006-04-20	Basf Ag	Verwendung stabiler Ammoniumsalze der Liponsäure zur Behandlung diabetischer und weiterer Störungen
WO2006042666A1 (de) *	2004-10-18	2006-04-27	Meda Pharma Gmbh & Co. Kg	R-(+)-α-LIPONSÄURE ZUR PRÄVENTION VON DIABETES
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
US20070055070A1 (en) *	2005-09-07	2007-03-08	Lawrence Lowell J	Novel esters of lipoic acid
US20070083054A1 (en) *	2005-10-12	2007-04-12	Lawrence Lowell J	Novel amides of lipoic acid
AU2007215240A1 (en) *	2006-02-10	2007-08-23	Multi Formulations Ltd.	Method for improving the oral administration of alpha-lipoic acid
US20070225354A1 (en) *	2006-03-21	2007-09-27	Eric Marchewitz	Use of dihydrolipoamide for enhancing physical performance
WO2008106640A1 (en) *	2007-03-01	2008-09-04	Cedars-Sinai Medical Center	Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
DE102007038849A1 (de)	2007-08-16	2009-02-19	Adscil Gmbh	Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US20090054513A1 (en) *	2007-08-22	2009-02-26	Response Scientific, Inc.	Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en)	2007-08-22	2011-05-17	Response Scientific, Inc.	Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US9028874B2 (en) *	2008-01-03	2015-05-12	Cedars-Sinai Medical Center	Antioxidant nanosphere comprising [1,2]-dithiolane moieties
MX2010009673A (es) *	2008-03-04	2011-03-15	Robert Shorr	Modulacion de la estructura, actividad y/o nivel de expresion enzimaticos.
DE202008005023U1 (de)	2008-04-11	2008-07-17	Day-Med-Concept Gmbh	Verwendung von α-Liponsäure und Coenzym Q10 zur selektiven Reduktion des visceralen Fettgewebes
WO2009148698A1 (en)	2008-06-02	2009-12-10	Cedars-Sinai Medical Center	Nanometer-sized prodrugs of nsaids
CA2744100C (en)	2008-10-21	2020-06-30	The General Hospital Corporation	Cell transplantation
US20100099751A1 (en) *	2008-10-21	2010-04-22	Al-Mulla Fahd	Method of treating diabetes-related vascular complications
WO2010052310A1 (en) *	2008-11-07	2010-05-14	Segix Italia S.R.L.	Alpha-lipoic acid derivatives and their use in drug preparation
WO2010060098A1 (en)	2008-11-24	2010-05-27	Cedars-Sinai Medical Center	Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
KR100935554B1 (ko) *	2009-06-24	2010-01-07	주식회사 셀트리온제약	피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물
KR101809301B1 (ko)	2010-08-06	2018-01-18	더 제너럴 하스피털 코포레이션 두잉 비즈니스 애즈 매사츄세츠 제너럴 하스피털	세포 처리 시스템 및 장치
WO2015001568A2 (en) *	2013-07-01	2015-01-08	Laurus Labs Private Limited	Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
CN115536631B (zh) *	2021-06-30	2024-01-30	江苏同禾药业有限公司	一种高纯度的右旋硫辛酸镁盐的制备方法
CN117263907B (zh) *	2023-09-23	2026-01-27	江西科技师范大学	一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1213141B (it) *	1984-02-17	1989-12-14	Dobrivoje Tomic	Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DE4218572A1 (de) *	1992-06-05	1993-12-09	Asta Medica Ag	Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) *	1993-12-21	1998-05-20	Asta Medica Ag	Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz

1993
- 1993-12-21 DE DE4343593A patent/DE4343593C2/de not_active Expired - Fee Related
1994
- 1994-12-17 ES ES99102285T patent/ES2258302T3/es not_active Expired - Lifetime
- 1994-12-17 DE DE59410429T patent/DE59410429D1/de not_active Expired - Lifetime
- 1994-12-17 DK DK94120045T patent/DK0659408T3/da active
- 1994-12-17 EP EP99102285A patent/EP0958816B1/de not_active Expired - Lifetime
- 1994-12-17 ES ES94120045T patent/ES2159539T3/es not_active Expired - Lifetime
- 1994-12-17 PT PT94120045T patent/PT659408E/pt unknown
- 1994-12-17 EP EP94120045A patent/EP0659408B1/de not_active Revoked
- 1994-12-17 PT PT99102285T patent/PT958816E/pt unknown
- 1994-12-17 DE DE59409810T patent/DE59409810D1/de not_active Revoked
- 1994-12-17 AT AT99102285T patent/ATE319444T1/de active
- 1994-12-17 DK DK99102285T patent/DK0958816T3/da active
- 1994-12-17 AT AT94120045T patent/ATE203669T1/de not_active IP Right Cessation
- 1994-12-20 CA CA002138558A patent/CA2138558C/en not_active Expired - Fee Related
- 1994-12-21 US US08/360,924 patent/US5693664A/en not_active Expired - Lifetime
- 1994-12-21 JP JP6318836A patent/JPH07206676A/ja active Pending
1997
- 1997-06-19 US US08/878,843 patent/US5948810A/en not_active Expired - Lifetime
1999
- 1999-04-02 US US09/285,460 patent/US6117899A/en not_active Expired - Fee Related
2000
- 2000-07-28 US US09/628,295 patent/US6284787B1/en not_active Expired - Fee Related
2001
- 2001-10-18 GR GR20010401812T patent/GR3036943T3/el not_active IP Right Cessation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998023606A1 (en) *	1996-11-27	1998-06-04	Fuji Kagaku Kogyo Kabushiki Kaisha	Cyclic dithio derivatives, remedies for diabetic kidney diseases, hypoglycemic agents, hypolipidemic agents, and lenitives for digestive disorders
JP2002516270A (ja) *	1998-05-28	2002-06-04	メディカルリサーチインスティチュート	リポ酸の制御放出
JP2000169371A (ja) *	1998-10-02	2000-06-20	Sankyo Co Ltd	ジチオラン誘導体を含有する医薬
JP2004508399A (ja) *	2000-09-12	2004-03-18	ビーエーエスエフ　アクチェンゲゼルシャフト	糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ
JP2004531567A (ja) *	2001-05-28	2004-10-14	エスパルマゲーエムベーハー	薬剤
JP2005002096A (ja) *	2003-05-21	2005-01-06	Oga Research:Kk	α−リポ酸含有水性製剤
JP2006321732A (ja) *	2005-05-18	2006-11-30	Fancl Corp	異常蛋白質除去及び８−ヒドロキシ２’−デオキシグアノシン増加抑制用組成物
WO2011152658A3 (en) *	2010-06-01	2012-04-26	Celltrion Chemical Research Institute	Pharmaceutical composition comprising piperazine dithioctate and glimepiride
JP2021059552A (ja) *	2014-10-20	2021-04-15	ヴァルビオティス	植物抽出物の混合物、またはこの植物中に含まれる分子の混合物を含有する組成物、ならびに糖質代謝及び／または脂質代謝を制御するための使用

Also Published As

Publication number	Publication date
ES2258302T3 (es)	2006-08-16
US5693664A (en)	1997-12-02
ATE203669T1 (de)	2001-08-15
GR3036943T3 (en)	2002-01-31
DE4343593A1 (de)	1995-06-22
CA2138558C (en)	2009-02-10
DE59409810D1 (de)	2001-09-06
US6284787B1 (en)	2001-09-04
ATE319444T1 (de)	2006-03-15
EP0659408A1 (de)	1995-06-28
EP0958816B1 (de)	2006-03-08
US5948810A (en)	1999-09-07
EP0958816A3 (de)	1999-12-15
DE4343593C2 (de)	1998-05-20
PT958816E (pt)	2006-06-30
ES2159539T3 (es)	2001-10-16
PT659408E (pt)	2001-12-28
DK0659408T3 (da)	2001-10-01
DK0958816T3 (da)	2006-07-17
DE59410429D1 (de)	2006-05-04
CA2138558A1 (en)	1995-06-22
HK1023943A1 (en)	2000-09-29
US6117899A (en)	2000-09-12
EP0958816A2 (de)	1999-11-24
EP0659408B1 (de)	2001-08-01

Publication	Publication Date	Title
US6284787B1 (en)	2001-09-04	Use of R-(+)-α-lipoic acid, R-(−)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
KR20010022786A (ko)	2001-03-26	당뇨병 치료를 위한 방법 및 조성물
NL8802634A (nl)	1989-05-16	Therapeutische preparaten.
ARTHUR MIRSKY et al.	1957	The hypoglycemic action of metabolic derivatives of L-tryptophan by mouth
Miguelez et al.	2016	L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo
CH655009A5 (it)	1986-03-27	Composizioni utili per la profilassi dell'iperlattacidemia.
AU2023205290A1 (en)	2024-07-11	Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof
TW201425290A (zh)	2014-07-01	化合物在製備用於治療糖尿病之組成物上的用途
US20230390364A1 (en)	2023-12-07	Use of human serum albumin in treatment of diseases
CN112316150B (zh)	2023-04-28	一种用于预防或治疗代谢或损伤相关疾病的药物组合物
EP1050309A1 (de)	2000-11-08	Förderer der sekretion von neurotrophen faktoren
BG65735B1 (bg)	2009-09-30	Приложение на алфа-липоева киселина или нейни прозводни за лечение на мигрена
WO2018166494A1 (zh)	2018-09-20	苦参碱衍生物在治疗糖尿病中的用途
US20080095741A1 (en)	2008-04-24	R-(+)-alpha-liponic acid for the prevention of diabetes
US20050176829A1 (en)	2005-08-11	Methods for treating hypothyroidism
US20050228035A1 (en)	2005-10-13	2-Pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
EP3811948B1 (de)	2024-09-11	Glycoside zur vorbeugung und behandlung diabetischer komplikationen
WO2022061962A1 (zh)	2022-03-31	一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
US20250009692A1 (en)	2025-01-09	Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
HK1023943B (en)	2006-09-01	Medicament for the treatment of diabetes mellitus as well as its subsequent disorders
CN109925280B (zh)	2021-06-01	一种硫辛酸注射液及其制备方法
US4219566A (en)	1980-08-26	Phenylglyoxylic acids and derivatives thereof
US4239779A (en)	1980-12-16	Use of phenylglyoxylic acids and derivatives thereof in the treatment of ischemic heart disease
CA2152796A1 (en)	1994-08-18	Use of inhibitors of ornithine aminotransferase for the manufacture of medicament for the treatment of alzheimer's disease
CN111228263A (zh)	2020-06-05	乙基甲基羟基吡啶苹果酸盐或其药物组合物，预防和/或治疗ⅱ型糖尿病的用途

JPH07206676A - 糖尿病の治療用薬剤 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=6505606

Family Applications (1)

Country Status (10)

Cited By (9)

Families Citing this family (60)

Family Cites Families (3)

Cited By (9)

Also Published As

Similar Documents